Real-world clinicogenomic evidence can help kidney drug developers move beyond broad CKD prevalence estimates to identify enriched patient populations for trial feasibility, RWE generation, and precision nephrology strategy. This brief highlights insights from RenasightIQ™, a kidney-specific longitudinal dataset integrating genomic, clinical, lab, and claims data. It provides a focused snapshot of CKD patients with diabetes and hypertension, including age, sex/gender, and U.S. geographic patterns that may help inform patient segmentation, site strategy, and evidence-generation planning.

Overview

• Real-world snapshot of CKD patients with diabetes and hypertension
• Approximately 211K CKD patients represented in the analyzed RenasightIQ™ cohort
• Longitudinal dataset integrating genomic, clinical, lab, and claims data
• Patient population characteristics, including age, sex/gender, and U.S. geography
• Signals that may inform CKD patient segmentation and development planning